57ACTIVITIES
1ORGS REPRESENTED
69BILLS
Organizations represented
1Orgs whose LD-2 filings list Teresa as an active lobbyist, sorted by activity volume.
Bills they file on
69S. 229632 mentions
S. 265822 mentions
S. 65214 mentions
S. 83214 mentions
S. 89114 mentions
S. 93214 mentions
H.R. 94614 mentions
H.R. 126214 mentions
H.R. 149214 mentions
H.R. 221414 mentions
S. 35513 mentions
S. 141413 mentions
S. 195413 mentions
S. 86412 mentions
H.R. 431712 mentions
+ 54 more bills referenced in their activities
Topics in Filings
90Policy topics Teresa files on across all their LD-2 activities.
One Big Beautiful Bill Act×35
Inflation Reduction Act×25
Drug cost and pricing policy×25
Rural Development×24
Supply chain policy×24
BIOSECURE Act×22
Most Favored Nation×22
Big Savings Act×20
RESTORE Patent Rights Act×20
Biopharmaceutical innovation policy×20
Modernizing and Ensuring PBM Accountability×14
Accountability, and Integrity Now and for the Future×14
Show all 90 topics (+78 more) ▾
Vaccine policy×14
Pharmacy Benefit Manager reform×14
Drug importation policy×14
FDA policy×14
Orphan Drug Act×14
Compounding policy×14
Clinical trial policy×14
Issues 340B drug discount program policy×14
Biosimilar approval and reimbursement policy×14
Artificial intelligence policy×14
FDA Modernization×14
Biosimilar Red Tape Elimination Act×13
Bipartisan Health Care Act×12
IRA price negotiation expansion policy×12
MAHA Commission Report×12
Make Our Children Healthy Again Competition policy×12
Issues 340B rebate pilot program Patient assistance program policy×12
Biosimilars Access and Affordability Act×12
Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H×11
Res. 566: Providing for consideration of the Senate amendment to the bill×11
Medication Affordability and Patent Integrity Act×11
Part D redesign and policy×11
Part B policy×11
Medicare rebate policy×11
Center for Medicare and Medicaid Innovation×11
Medicaid rebate policy×11
PBM Price Transparency and Accountability Act×11
Mikaela Naylon Give Kids a Chance Act×11
PBM Reform×11
HELP Copays Act×11
Antimicrobial resistance policy×11
Energy and Water Development×10
Legislative Branch×10
Military Construction and Veterans Affairs, and Extensions Act, 2026×10
Government funding policy×10
Skinny Labels×10
Affordable Prescriptions for Patients Act×10
Stop STALLING Act×10
Preserve Access to Affordable Generics and Biosimilars Act×10
Interagency Patent Coordination and Improvement Act×10
Stopping Pharmas Ripoffs and Drug Savings For All Act×10
Bayh-Dole march-in rights policy×10
Patent thicket policy×10
AI patent policy×10
Patent eligibility policy×10
Post-grant proceeding policy×10
Patent submission policy×10
Patent fee policy×10
CLEAR LABELS Act×10
Most Favored Patients Act×10
FAIR ACT×10
SECURE Rx Act×10
GENErating cost Reductions for U.S×10
Medicare Against Rising Drugs Costs×10
International intellectual property and market access policy×10
Pricing and reimbursement policy×10
WTO TRIPS waiver policy×10
China outbound investment policy×10
US-UK Framework Agreement×10
User fee issues×4
Give Kids a Chance Act×3
Antimicrobial resistance×3
Accelerated approval policy×2
Competition policy×2
Patient assistance program policy×2
Drug shortages policy×2
Science, and Related Agencies Appropriations Act, 2026×2
Protecting Patients from Deceptive Drug Ads Act×1
Innovation in Pediatric Drugs Act×1
Pandemic preparedness policy×1
Military Construction×1
Expedited Acccess to Biosimilars Act×1
MAPS Act×1
Orphan Cures Act×1
Prescription Information Modernization×1
Insulin policy×1
Medicaid waiver policy×1
Open Payments Expansion Act×1
Issue mix
LDA general-issue codes weighted by activity count.
Health Issues14
Budget/Appropriations12
Medicare/Medicaid11
Copyright/Patent/Trademark10
Trade (domestic/foreign)10